Thu. 9 May 2024, 8:43am ET
Benzinga
Biotech, News, Legal, General
Patent, once issued, will provide composition protection through 2040, with potential for additional term extension
Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway